C12N 2750/14151
Methods of production or purification of viral material
C12N2750/14151 (Methods of production or purification of viral material) appears on 445 US grants and 1,096 published applications in this corpus.
Search patents in C12N- Granted patents
- 445
- Published applications
- 1,096
- Assignees
- 363
- Inventors
- 1,878
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 1 |
| 2002 | 13 | 18 |
| 2003 | 9 | 17 |
| 2004 | 5 | 18 |
| 2005 | 9 | 11 |
| 2006 | 10 | 7 |
| 2007 | 6 | 11 |
| 2008 | 4 | 6 |
| 2009 | 6 | 11 |
| 2010 | 6 | 5 |
| 2011 | 4 | 9 |
| 2012 | 6 | 8 |
| 2013 | 4 | 12 |
| 2014 | 7 | 12 |
| 2015 | 13 | 19 |
| 2016 | 14 | 30 |
| 2017 | 12 | 30 |
| 2018 | 20 | 36 |
| 2019 | 23 | 46 |
| 2020 | 33 | 64 |
| 2021 | 33 | 84 |
| 2022 | 32 | 99 |
| 2023 | 39 | 121 |
| 2024 | 41 | 134 |
| 2025 | 42 | 148 |
| 2026 | 38 | 139 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- ABCD1 for treatment of neurodisorders15 Sep 2026US 12,735,706 B2The General Hospital Corporation
- Recombinant adeno-associated virus compositions and methods for producing same8 Sep 2026US 12,729,385 B2Prevail Therapeutics, Inc.
- AAV production strategy using a cell line expressing an inducible rep gene1 Sep 2026US 12,723,249 B2University of Massachusetts
- Methods of treating neurodegenerative disorders8 Oct 2026US 2026/0306669 A1
- Hybrid transient transfection using transposase for high yield product production8 Oct 2026US 2026/0308275 A1Lonza Biologics PLC
- Targeting aav capsids, methods of manufacturing and using same8 Oct 2026US 2026/0308615 A1REGENXBIO Inc.
- Compositions and methods for recombinant aav production8 Oct 2026US 2026/0308620 A1REGENXBIO Inc.
- Single plasmid system for aav production8 Oct 2026US 2026/0308623 A1Solid Biosciences Inc.
Most cited
By later US patents
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Hybrid adenovirus-AAV virus and methods of use thereof311US 5,871,982 AThe Trustees of the University of Pennsylvania · 1999
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor220US 7,790,449 B2The Trustees of the University of Pennsylvania · 2010
- Compositions and methods for helper-free production of recombinant adeno-associated viruses184US 6,258,595 B1The Trustees of the University of Pennsylvania · 2001